Cell Therapy
Gene Editing
Scaling Up
Viral/Non-Viral Vectors

Case Study: Process Development and Large-Scale GMP Production for Lentiviral Vectors

Phacilitate
11 June 2020
SHARE NOW

Vibrant communities and market intelligence.

Advanced Therapies Week

2022, Miami, Florida.
Book Today

How efficient are your lentiviral vector large-scale production and purification processes?

MolMed offers in-house proprietary processes for lentiviral (LV) vector production at large scale. As the evolution of the well-established GMP 48L CF process MolMed is developing a robust and scalable process for the industrial-scale production of both LV vectors for use in gene-modified cell therapy using a scalable platform that includes the iCELLis bioreactor vector production and a downstream purification platform that includes chromatography and TFF steps.

In this session, you are presented with a wealth of productivity and quality data obtained with the CF process and the development and optimisation of the LV production process in a bioreactor.

During this webinar, you will learn:

  • How to perform an efficient LV vector large-scale production and purification processes
  • Process development and large-scale production process using the iCELLis platform
  • How to design an industrial scale viral vector production from bulk production to final filled product

Advanced Therapies Week

2022, Miami, Florida.
Book Today